Compagnie Lombard Odier SCmA’s PDL BioPharma, Inc. PDLI Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,720	Closed	-$6K	–	907
2016 Q4	$6K	Hold	2,720	–	–	﹤0.01%	774
2016 Q3	$9K	Hold	2,720	–	–	﹤0.01%	855
2016 Q2	$9K	Hold	2,720	–	–	﹤0.01%	845
2016 Q1	$9K	Hold	2,720	–	–	﹤0.01%	899
2015 Q4	$10K	Hold	2,720	–	–	﹤0.01%	861
2015 Q3	$14K	Hold	2,720	–	–	﹤0.01%	730
2015 Q2	$17K	Sell	2,720 -1,500	-36%	-$10K	﹤0.01%	727
2015 Q1	$30K	Buy	+4,220	New	+$30.6K	﹤0.01%	831

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Compagnie Lombard Odier SCmA's PDLI Position: Q1 2017 in Review

Compagnie Lombard Odier SCmA sold out of PDL BioPharma, Inc. (PDLI) in Q1 2017, closing a stake of 2,720 shares — an estimated $6K sold.

Compagnie Lombard Odier SCmA first reported a position in PDLI in Q1 2015 and held it in 8 quarters. The position peaked at $30K in Q1 2015. 174 funds tracked by Wall St. Rank hold PDLI as of Q1 2017.

Compagnie Lombard Odier SCmA reported no remaining PDL BioPharma, Inc. position as of Q1 2017 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 2,720 PDL BioPharma, Inc. shares in Q1 2017, an estimated $6K.
Compagnie Lombard Odier SCmA first reported a position in PDL BioPharma, Inc. in Q1 2015 and held it in 8 quarters.
Compagnie Lombard Odier SCmA's PDL BioPharma, Inc. position peaked at $30K in Q1 2015.
174 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2017, filed 15 May 2017.